trending Market Intelligence /marketintelligence/en/news-insights/trending/Mjm1GR6Hk0BWFrfdALuDmg2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

US FDA grants orphan status to OncoSec's cancer drug

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

US FDA grants orphan status to OncoSec's cancer drug

The U.S. Food and Drug Administration granted an orphan drug designation to OncoSec Medical Inc.'s pIL-12, known as tavokinogene telsaplasmid, for the treatment of unresectable metastatic melanoma.

Tavokinogene telsaplasmid is the active biologic agent in ImmunoPulse IL-12, the company's lead product candidate.

OncoSec said the designation will provide the company with eligibility for certain development incentives, including tax credits for clinical testing, exemption from a prescription drug user fee, and seven years of market exclusivity.

The company is starting a phase 2 trial of the product in combination with Keytruda in patients with metastatic melanoma following disease progression on previous treatment with an anti-PD-1 therapy.